Automated Insulin Delivery (AID) Systems: Use and Efficacy in Children and Adults with Type 1 Diabetes and Other Forms of Diabetes in Europe in Early 2023

Overview

Journal Life (Basel)

Specialty Biology

Date 2023 Mar 29

PMID 36983941

Authors

Marta Bassi

Daniele Franzone

Francesca Dufour

Marina Francesca Strati

Marta Scalas

Giacomo Tantari

Concetta Aloi

Alessandro Salina

Giuseppe DAnnunzio

Mohamad Maghnie

Nicola Minuto

Affiliations

Soon will be listed here.

Abstract

Type 1 diabetes (T1D) patients' lifestyle and prognosis has remarkably changed over the years, especially after the introduction of insulin pumps, in particular advanced hybrid closed loop systems (AHCL). Emerging data in literature continuously confirm the improvement of glycemic control thanks to the technological evolution taking place in this disease. As stated in previous literature, T1D patients are seen to be more satisfied thanks to the use of these devices that ameliorate not only their health but their daily life routine as well. Limited findings regarding the use of new devices in different age groups and types of patients is their major limit. This review aims to highlight the main characteristics of each Automated Insulin Delivery (AID) system available for patients affected by Type 1 Diabetes Mellitus. Our main goal was to particularly focus on these systems' efficacy and use in different age groups and populations (i.e., children, pregnant women). Recent studies are emerging that demonstrate their efficacy and safety in younger patients and other forms of diabetes.

Citing Articles

What is the Relationship Between Time in Range, Time in Tight Range, and HbA1c in Youth and Young Adults With Type 1 Diabetes? Results From the German/Austrian/Luxembourgian/Swiss Diabetes Prospective Follow-Up Registry.

Burckhardt M, Auzanneau M, Rosenbauer J, Binder E, Weiskorn J, Hess M J Diabetes Sci Technol. 2024; :19322968241288870.

PMID: 39548894 PMC: 11571145. DOI: 10.1177/19322968241288870.

Twelve-Month Real-World Use of an Advanced Hybrid Closed-Loop System Versus Previous Therapy in a Dutch Center For Specialized Type 1 Diabetes Care.

Dekker P, Van den Heuvel T, Arrieta A, Castaneda J, Mul D, Veeze H J Diabetes Sci Technol. 2024; :19322968241290259.

PMID: 39465557 PMC: 11571609. DOI: 10.1177/19322968241290259.

Advances in diabetes technology within the digital diabetes ecosystem.

Akturk H, Bindal A J Manag Care Spec Pharm. 2024; 30(10-b Suppl):S7-S20.

PMID: 39347970 PMC: 11443980. DOI: 10.18553/jmcp.2024.30.10-b.s7.

Innovation is the driver behind quality improvements in diabetes care delivery.

Hirsch I, Parkin C J Manag Care Spec Pharm. 2024; 30(10-b Suppl):S2-S6.

PMID: 39347969 PMC: 11443978. DOI: 10.18553/jmcp.2024.30.10-b.s2.

Reinforcement Learning: A Paradigm Shift in Personalized Blood Glucose Management for Diabetes.

Denes-Fazakas L, Szilagyi L, Kovacs L, De Gaetano A, Eigner G Biomedicines. 2024; 12(9).

PMID: 39335656 PMC: 11429314. DOI: 10.3390/biomedicines12092143.

References

Ly T, Roy A, Grosman B, Shin J, Campbell A, Monirabbasi S . Day and Night Closed-Loop Control Using the Integrated Medtronic Hybrid Closed-Loop System in Type 1 Diabetes at Diabetes Camp. Diabetes Care. 2015; 38(7):1205-11. DOI: 10.2337/dc14-3073. View

Quemerais M, Doron M, Dutrech F, Melki V, Franc S, Antonakios M . Preliminary evaluation of a new semi-closed-loop insulin therapy system over the prandial period in adult patients with type 1 diabetes: the WP6.0 Diabeloop study. J Diabetes Sci Technol. 2014; 8(6):1177-84. PMC: 4455472. DOI: 10.1177/1932296814545668. View

Hovorka R, Elleri D, Thabit H, Allen J, Leelarathna L, El-Khairi R . Overnight closed-loop insulin delivery in young people with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care. 2014; 37(5):1204-11. PMC: 3994941. DOI: 10.2337/dc13-2644. View

Hovorka R, Kumareswaran K, Harris J, Allen J, Elleri D, Xing D . Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ. 2011; 342:d1855. PMC: 3077739. DOI: 10.1136/bmj.d1855. View

Schoelwer M, Sherr J, Weyman K, Tichy E, VanName M, Brei M . Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial. Diabetes Care. 2022; 45(8):1907-1910. PMC: 9346983. DOI: 10.2337/dc21-2359. View

Benhamou P, Huneker E, Franc S, Doron M, Charpentier G . Customization of home closed-loop insulin delivery in adult patients with type 1 diabetes, assisted with structured remote monitoring: the pilot WP7 Diabeloop study. Acta Diabetol. 2018; 55(6):549-556. DOI: 10.1007/s00592-018-1123-1. View

Tauschmann M, Allen J, Wilinska M, Thabit H, Acerini C, Dunger D . Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Suboptimally Controlled Adolescents With Type 1 Diabetes: A 3-Week, Free-Living, Randomized Crossover Trial. Diabetes Care. 2016; 39(11):2019-2025. PMC: 5079605. DOI: 10.2337/dc16-1094. View

Benhamou P, Lablanche S, Vambergue A, Doron M, Franc S, Charpentier G . Patients with highly unstable type 1 diabetes eligible for islet transplantation can be managed with a closed-loop insulin delivery system: A series of N-of-1 randomized controlled trials. Diabetes Obes Metab. 2020; 23(1):186-194. DOI: 10.1111/dom.14214. View

Boughton C, Hovorka R . New closed-loop insulin systems. Diabetologia. 2021; 64(5):1007-1015. PMC: 8012332. DOI: 10.1007/s00125-021-05391-w. View

10.

Kariyawasam D, Morin C, Casteels K, Le Tallec C, Sfez A, Godot C . Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6-12 years: a randomised, controlled, cross-over, non-inferiority trial. Lancet Digit Health. 2022; 4(3):e158-e168. DOI: 10.1016/S2589-7500(21)00271-5. View

11.

Boughton C, Tripyla A, Hartnell S, Daly A, Herzig D, Wilinska M . Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial. Nat Med. 2021; 27(8):1471-1476. PMC: 8363503. DOI: 10.1038/s41591-021-01453-z. View

12.

Brown S, Kovatchev B, Raghinaru D, Lum J, Buckingham B, Kudva Y . Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. N Engl J Med. 2019; 381(18):1707-1717. PMC: 7076915. DOI: 10.1056/NEJMoa1907863. View

13.

Lum J, Bailey R, Barnes-Lomen V, Naranjo D, Hood K, Lal R . A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery System. Diabetes Technol Ther. 2020; 23(5):367-375. PMC: 8080906. DOI: 10.1089/dia.2020.0535. View

14.

Bally L, Thabit H, Hartnell S, Andereggen E, Ruan Y, Wilinska M . Closed-Loop Insulin Delivery for Glycemic Control in Noncritical Care. N Engl J Med. 2018; 379(6):547-556. DOI: 10.1056/NEJMoa1805233. View

15.

Petrovski G, Al Khalaf F, Campbell J, Day E, Almajaly D, Hussain K . Glycemic outcomes of Advanced Hybrid Closed Loop system in children and adolescents with Type 1 Diabetes, previously treated with Multiple Daily Injections (MiniMed 780G system in T1D individuals, previously treated with MDI). BMC Endocr Disord. 2022; 22(1):80. PMC: 8962027. DOI: 10.1186/s12902-022-00996-7. View

16.

Breton M, Kovatchev B . One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology. Diabetes Technol Ther. 2021; 23(9):601-608. PMC: 8501470. DOI: 10.1089/dia.2021.0097. View

17.

Bassi M, Teliti M, Lezzi M, Iosca A, Strati M, Carmisciano L . A Comparison of Two Hybrid Closed-Loop Systems in Italian Children and Adults With Type 1 Diabetes. Front Endocrinol (Lausanne). 2022; 12:802419. PMC: 8805205. DOI: 10.3389/fendo.2021.802419. View

18.

Pulkkinen M, Varimo T, Hakonen E, Harsunen M, Hyvonen M, Janer J . MiniMed 780G™ in 2- to 6-Year-Old Children: Safety and Clinical Outcomes After the First 12 Weeks. Diabetes Technol Ther. 2022; 25(2):100-107. DOI: 10.1089/dia.2022.0313. View

19.

Boughton C, Hartnell S, Thabit H, Poettler T, Herzig D, Wilinska M . Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study. Diabetes Obes Metab. 2021; 23(6):1389-1396. PMC: 11497277. DOI: 10.1111/dom.14355. View

20.

Tauschmann M, Allen J, Nagl K, Fritsch M, Yong J, Metcalfe E . Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Very Young Children: A Multicenter, 3-Week, Randomized Trial. Diabetes Care. 2019; 42(4):594-600. DOI: 10.2337/dc18-1881. View